Related Experiment Video
Updated: Jul 2, 2025

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution
Published on: September 21, 2012
MUC17 is an essential small intestinal glycocalyx component that is disrupted in Crohn's disease
Elena Layunta1, Sofia Jäverfelt1, Fleur C van de Koolwijk1
1Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Box 440, 405 30 Gothenburg, Sweden.
Abstract:
Crohn's disease (CD) is the chronic inflammation of the ileum and colon triggered by bacteria, but insights into molecular perturbations at the bacteria-epithelium interface are limited. We report that membrane mucin MUC17 protects small intestinal enterocytes against commensal and pathogenic bacteria. In non-inflamed CD ileum, reduced MUC17 levels correlated with a compromised glycocalyx, allowing bacterial contact with enterocytes. Muc17 deletion in mice rendered the small intestine prone to atypical infection while maintaining resistance to colitis. The loss of Muc17 resulted in spontaneous deterioration of epithelial homeostasis and extra-intestinal translocation of bacteria. Finally, Muc17-deficient mice harbored specific small intestinal bacterial taxa observed in CD. Our findings highlight MUC17 as an essential line of defense in the small intestine with relevance for early epithelial defects in CD.
Insights
The membrane mucin MUC17 protects the small intestine from bacteria. Reduced MUC17 levels in Crohn
Area of Science:
- Gastroenterology and Immunology
- Microbiome Research
- Epithelial Biology
Background:
- Crohn's disease (CD) involves chronic intestinal inflammation, but the bacterial-epithelial interactions are not fully understood.
- The role of specific molecules at the host-microbe interface in CD pathogenesis remains unclear.
- Membrane mucins are crucial for intestinal barrier function, yet their specific roles in CD are under-investigated.
Conclusions:
- MUC17 is a critical component of the small intestinal epithelial defense system against bacterial invasion.
- Deficiency in MUC17 may contribute to early epithelial defects observed in Crohn's disease by compromising barrier function and altering the microbiome.
- Targeting MUC17 or restoring its function could represent a novel therapeutic strategy for managing early-stage Crohn's disease.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
07:39Author Spotlight: Investigating the Effects of Compounds on Intestinal Tissue Using 3D Human Cell Line Models
Published on: September 1, 2023
Related Concept Videos
Renewal of Intestinal Stem Cells
Mucosal Barrier of the Stomach
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Glycocalyx and its Functions
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors